Does pharmacogenetic testing optimize antidepressant effectiveness in major depressive disorder? Data from a double-blind randomized controlled trial in a real-world clinical setting

Abstract Background Major depressive disorder (MDD) exhibits significant heterogeneity in treatment responses, necessitating multiple pharmacological trials to achieve therapeutic success. Pharmacogenetic (PGx) testing has emerged as a promising tool to personalize antidepressant (AD) treatments, th...

Descripció completa

Dades bibliogràfiques

Autors principals:	Alessandra Minelli, Stefano Barlati, Stefano Bignotti, Valentina Menesello, Gabriele Nibbio, Giulia Perusi, Alessia Muscarella, Lisa Buson, Ughetta Bosco Umbertino, Paolo Martini, Rosana Carvalho Silva, Edoardo Spina, Giovanni Battista Tura, Antonio Vita, Massimo Gennarelli
Format:	Artigo
Idioma:	Inglês
Publicat:	Cambridge University Press 2025-01-01
Col·lecció:	European Psychiatry
Matèries:	antidepressant treatment depression genetics pharmacogenetic testing randomized controlled trial
Accés en línia:	https://www.cambridge.org/core/product/identifier/S0924933825101326/type/journal_article
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!